Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

My top 10 things to watch Tuesday, Jan. 27 1. The S & P 500 was headed for a slightly higher open this morning ahead of Big Tech earnings tomorrow evening (Meta Platforms and Microsoft ) and Thursday ...

Eli Lilly's oral GLP-1 candidate, orforglipron, won't earn approval as fast as the company expected. Meanwhile, a notable ...

In the latest trading session, Eli Lilly (LLY) closed at $1,064.29, marking a -2.12% move from the previous day. This change lagged the S&P 500's 0.03% gain on the day. Elsewhere, the Dow saw a ...

Novo Nordisk A/S is rated a Buy with solid long-term prospects, and the stock appears undervalued. Learn more about NVO stock ...

It feels like a great rotation out of the Magnificent Seven has already kicked off just over a quarter ago. Undoubtedly, the ...

One exchange-traded fund (ETF) that tracks the Large Cap Growth Index is the Vanguard Growth ETF ( VUG +0.68%). It has ...

The S&P 500 advanced this morning as Wall Street cheered signs of easing geopolitical tensions. Traders are also awaiting key inflation data.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Welcome to Episode #471 of the Zacks Market Edge Podcast. Every week, host and Zacks stock strategist, Tracey Ryniec, will be ...

Alumis, Aktis Oncology, and W.R. Berkley saw significant insider buying last week. There were a handful of other notable ...